Morgan Stanley (NYSE:MS) initiated coverage on shares of GlaxoSmithKline (NYSE:GSK:LN) (NYSE: GSK), a $72.5 billion pharmaceutical giant with a 25-year track record of consistent dividend payments, ...

Gilead Sciences, Inc. GILD reported better-than-expected fourth-quarter results and provided an upbeat guidance for 2025.

Its UK #NationalApprenticeshipWeek, so we've put together a list of our top ten manufacturing apprenticeship schemes led by ...

Royalty Pharma to provide R&D investment of up to $250 million for Biogen’s litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupusNEW YORK, Feb. 12, 2025 ...

Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D) funding of up ...

Over the last few years, this under-the-radar technology business has quietly become one of the largest companies in the FTSE ...

Not all mouthwashes are created equal, though, so I spoke to five dentists for their expert recommendations and tried out a ...

A professional investor tells us where he’d put his money. This week: Charlie Huggins, manager of Wealth Club’s Quality ...

In early UK corporate news, housebuilder Barratt Redrow said it expects annual profit to land at the top end of consensus. Merchant bank Close Brothers revealed a GBP165 million provision set aside in ...

GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN –– Approval based on positive data ...

That's on top of any financial institution sign-on bonuses. Get access by joining NerdWallet+. All eligible products require partner approval. See partner terms and conditions before applying.

The heart drug digoxin could potentially be combined with existing cancer therapies to prevent the spread of tumors, an early ...